(Q57927969)

English

Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme

No description defined

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme (English)

0 references

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

object named as

Shomik Maruf

10

0 references

13

object named as

Dinesh Mondal

0 references

8

object named as

Rashidul Haque

0 references

author name string

Md Sakhawat Hossain

1

0 references

Amresh Kumar

2

0 references

A F M Akhtar Hossain

3

0 references

Md Mahshin

4

0 references

Abhijit Sharma

5

0 references

Md Akter Hossain

6

0 references

Varun Sharma

7

0 references

A K M Shamsuzzaman

9

0 references

Prakash Ghosh

11

0 references

Vivek Ahuja

12

0 references

language of work or name

0 references

publication date

13 August 2018

0 references

Infectious Diseases of Poverty

0 references

7

0 references

1

0 references

80

0 references

copyright license

Creative Commons Attribution 4.0 International

13 August 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

AmBisome Induced Avascular Necrosis of the Alae of the Nose of a very young girl suffering from Kala-azar - a Case Report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Visceral leishmaniasis-associated mortality in Bangladesh: a retrospective cross-sectional study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Leishmaniasis worldwide and global estimates of its incidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6088425

30 November 2018

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30099967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30099967

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S40249-018-0461-0

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57927969&oldid=2222109415"